A prospective evaluation of clinical and genetic predictors of weight changes in breast cancer survivors
| Autor: | Lesya Zaichenko, Silvia Aki McCandlish, Donna P. Ankerst, Panagiota Oikonomopoulou, Julie Paulus, Iram Dubin, Regina Uthe, Virginia G. Kaklamani, Christos S. Mantzoros, Linda Van Horn, Surbhi Agarwl, Yanfei Xu, Katharina Selig, Maureen Sadim |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty education.field_of_study Adiponectin business.industry Population Cancer medicine.disease Obesity 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Breast cancer 030220 oncology & carcinogenesis Internal medicine medicine medicine.symptom Prospective cohort study education business Body mass index Weight gain |
| Zdroj: | Cancer. 123:2413-2421 |
| ISSN: | 0008-543X |
| DOI: | 10.1002/cncr.30628 |
| Popis: | BACKGROUND Postdiagnosis weight gain in patients with breast cancer has been associated with increased cancer recurrence and mortality. This study was designed to identify risk factors for weight gain and create a predictive model to identify a high-risk population for targeted interventions. METHODS The weight of 393 patients with breast cancer from the Northwestern Robert H. Lurie Cancer Center was measured over a 2-year period from diagnosis, with body mass index (BMI) change over 18 months as the primary endpoint. Demographics, clinical factors, treatment methods, as well as tumor characteristics were also recorded; and a lifestyle questionnaire was conducted. Blood samples were genotyped for 16 single nucleotide polymorphisms in FTO, adiponectin pathway genes (ADIPOQ, ADIPOR1), and FNDC5. Serum leptin, adiponectin, and irisin levels also were measured. RESULTS Mean ± standard deviation 18-month BMI changes were 0.68 ± 1.42, 0.98 ± 1.62, 0.79 ± 1.74, and −0.44 ± 1.58 kg/m2 for patients ages |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text